nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—Cough—Cyclosporine—psoriasis	0.000974	0.00123	CcSEcCtD
Loxapine—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000972	0.00123	CcSEcCtD
Loxapine—Fatigue—Mycophenolic acid—psoriasis	0.000971	0.00123	CcSEcCtD
Loxapine—Convulsion—Cyclosporine—psoriasis	0.000967	0.00122	CcSEcCtD
Loxapine—Asthenia—Hydroxyurea—psoriasis	0.000965	0.00122	CcSEcCtD
Loxapine—Weight increased—Prednisone—psoriasis	0.000964	0.00122	CcSEcCtD
Loxapine—Hypertension—Cyclosporine—psoriasis	0.000964	0.00122	CcSEcCtD
Loxapine—Constipation—Mycophenolic acid—psoriasis	0.000963	0.00122	CcSEcCtD
Loxapine—Weight decreased—Prednisone—psoriasis	0.000958	0.00121	CcSEcCtD
Loxapine—Vision blurred—Prednisolone—psoriasis	0.000957	0.00121	CcSEcCtD
Loxapine—Loss of consciousness—Mycophenolate mofetil—psoriasis	0.000957	0.00121	CcSEcCtD
Loxapine—Chest pain—Cyclosporine—psoriasis	0.00095	0.0012	CcSEcCtD
Loxapine—Cough—Mycophenolate mofetil—psoriasis	0.00095	0.0012	CcSEcCtD
Loxapine—Convulsion—Mycophenolate mofetil—psoriasis	0.000943	0.00119	CcSEcCtD
Loxapine—Hypertension—Mycophenolate mofetil—psoriasis	0.00094	0.00119	CcSEcCtD
Loxapine—Dry mouth—Cyclosporine—psoriasis	0.000929	0.00118	CcSEcCtD
Loxapine—Feeling abnormal—Mycophenolic acid—psoriasis	0.000928	0.00117	CcSEcCtD
Loxapine—Chest pain—Mycophenolate mofetil—psoriasis	0.000927	0.00117	CcSEcCtD
Loxapine—Confusional state—Cyclosporine—psoriasis	0.000918	0.00116	CcSEcCtD
Loxapine—Dysgeusia—Triamcinolone—psoriasis	0.000915	0.00116	CcSEcCtD
Loxapine—Oedema—Cyclosporine—psoriasis	0.000911	0.00115	CcSEcCtD
Loxapine—Syncope—Prednisolone—psoriasis	0.000911	0.00115	CcSEcCtD
Loxapine—Dry mouth—Mycophenolate mofetil—psoriasis	0.000907	0.00115	CcSEcCtD
Loxapine—Confusional state—Mycophenolate mofetil—psoriasis	0.000896	0.00113	CcSEcCtD
Loxapine—Nervous system disorder—Cyclosporine—psoriasis	0.000893	0.00113	CcSEcCtD
Loxapine—Loss of consciousness—Prednisolone—psoriasis	0.000893	0.00113	CcSEcCtD
Loxapine—Thrombocytopenia—Cyclosporine—psoriasis	0.000892	0.00113	CcSEcCtD
Loxapine—Syncope—Hydrocortisone—psoriasis	0.00089	0.00113	CcSEcCtD
Loxapine—Dizziness—Hydroxyurea—psoriasis	0.000889	0.00113	CcSEcCtD
Loxapine—Oedema—Mycophenolate mofetil—psoriasis	0.000889	0.00112	CcSEcCtD
Loxapine—Angiopathy—Betamethasone—psoriasis	0.000883	0.00112	CcSEcCtD
Loxapine—Angiopathy—Dexamethasone—psoriasis	0.000883	0.00112	CcSEcCtD
Loxapine—Convulsion—Prednisolone—psoriasis	0.00088	0.00111	CcSEcCtD
Loxapine—Hypertension—Prednisolone—psoriasis	0.000877	0.00111	CcSEcCtD
Loxapine—Shock—Mycophenolate mofetil—psoriasis	0.000874	0.00111	CcSEcCtD
Loxapine—Loss of consciousness—Hydrocortisone—psoriasis	0.000872	0.0011	CcSEcCtD
Loxapine—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000871	0.0011	CcSEcCtD
Loxapine—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.00087	0.0011	CcSEcCtD
Loxapine—Tachycardia—Mycophenolate mofetil—psoriasis	0.000867	0.0011	CcSEcCtD
Loxapine—Alopecia—Dexamethasone—psoriasis	0.00086	0.00109	CcSEcCtD
Loxapine—Alopecia—Betamethasone—psoriasis	0.00086	0.00109	CcSEcCtD
Loxapine—Convulsion—Hydrocortisone—psoriasis	0.000859	0.00109	CcSEcCtD
Loxapine—Hypertension—Hydrocortisone—psoriasis	0.000856	0.00108	CcSEcCtD
Loxapine—Vomiting—Hydroxyurea—psoriasis	0.000855	0.00108	CcSEcCtD
Loxapine—Rash—Hydroxyurea—psoriasis	0.000848	0.00107	CcSEcCtD
Loxapine—Dermatitis—Hydroxyurea—psoriasis	0.000847	0.00107	CcSEcCtD
Loxapine—Headache—Hydroxyurea—psoriasis	0.000842	0.00107	CcSEcCtD
Loxapine—Syncope—Triamcinolone—psoriasis	0.000838	0.00106	CcSEcCtD
Loxapine—Hypotension—Mycophenolate mofetil—psoriasis	0.00083	0.00105	CcSEcCtD
Loxapine—Oedema—Prednisolone—psoriasis	0.000829	0.00105	CcSEcCtD
Loxapine—Insomnia—Cyclosporine—psoriasis	0.000824	0.00104	CcSEcCtD
Loxapine—Loss of consciousness—Triamcinolone—psoriasis	0.000821	0.00104	CcSEcCtD
Loxapine—Paraesthesia—Cyclosporine—psoriasis	0.000818	0.00104	CcSEcCtD
Loxapine—Shock—Prednisolone—psoriasis	0.000816	0.00103	CcSEcCtD
Loxapine—Cough—Triamcinolone—psoriasis	0.000815	0.00103	CcSEcCtD
Loxapine—Dyspnoea—Cyclosporine—psoriasis	0.000812	0.00103	CcSEcCtD
Loxapine—Somnolence—Cyclosporine—psoriasis	0.00081	0.00102	CcSEcCtD
Loxapine—Oedema—Hydrocortisone—psoriasis	0.00081	0.00102	CcSEcCtD
Loxapine—Convulsion—Triamcinolone—psoriasis	0.000809	0.00102	CcSEcCtD
Loxapine—Tachycardia—Prednisolone—psoriasis	0.000809	0.00102	CcSEcCtD
Loxapine—Photosensitivity reaction—Methotrexate—psoriasis	0.000808	0.00102	CcSEcCtD
Loxapine—Asthenia—Mycophenolic acid—psoriasis	0.000808	0.00102	CcSEcCtD
Loxapine—Hypertension—Triamcinolone—psoriasis	0.000806	0.00102	CcSEcCtD
Loxapine—Insomnia—Mycophenolate mofetil—psoriasis	0.000804	0.00102	CcSEcCtD
Loxapine—Nausea—Hydroxyurea—psoriasis	0.000799	0.00101	CcSEcCtD
Loxapine—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000798	0.00101	CcSEcCtD
Loxapine—Pruritus—Mycophenolic acid—psoriasis	0.000797	0.00101	CcSEcCtD
Loxapine—Shock—Hydrocortisone—psoriasis	0.000796	0.00101	CcSEcCtD
Loxapine—Nervous system disorder—Hydrocortisone—psoriasis	0.000794	0.001	CcSEcCtD
Loxapine—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000792	0.001	CcSEcCtD
Loxapine—Tachycardia—Hydrocortisone—psoriasis	0.00079	0.001	CcSEcCtD
Loxapine—Somnolence—Mycophenolate mofetil—psoriasis	0.00079	0.001	CcSEcCtD
Loxapine—Drowsiness—Methotrexate—psoriasis	0.000789	0.000999	CcSEcCtD
Loxapine—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000786	0.000995	CcSEcCtD
Loxapine—Fatigue—Cyclosporine—psoriasis	0.000785	0.000994	CcSEcCtD
Loxapine—Constipation—Cyclosporine—psoriasis	0.000779	0.000986	CcSEcCtD
Loxapine—Dry mouth—Triamcinolone—psoriasis	0.000778	0.000984	CcSEcCtD
Loxapine—Renal failure—Methotrexate—psoriasis	0.000776	0.000982	CcSEcCtD
Loxapine—Angiopathy—Prednisone—psoriasis	0.000769	0.000973	CcSEcCtD
Loxapine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000767	0.000971	CcSEcCtD
Loxapine—Oedema—Triamcinolone—psoriasis	0.000762	0.000965	CcSEcCtD
Loxapine—Syncope—Dexamethasone—psoriasis	0.00076	0.000962	CcSEcCtD
Loxapine—Syncope—Betamethasone—psoriasis	0.00076	0.000962	CcSEcCtD
Loxapine—Constipation—Mycophenolate mofetil—psoriasis	0.00076	0.000962	CcSEcCtD
Loxapine—Hypotension—Hydrocortisone—psoriasis	0.000756	0.000957	CcSEcCtD
Loxapine—Feeling abnormal—Cyclosporine—psoriasis	0.000751	0.00095	CcSEcCtD
Loxapine—Shock—Triamcinolone—psoriasis	0.00075	0.000949	CcSEcCtD
Loxapine—Insomnia—Prednisolone—psoriasis	0.00075	0.000949	CcSEcCtD
Loxapine—Alopecia—Prednisone—psoriasis	0.000749	0.000948	CcSEcCtD
Loxapine—Loss of consciousness—Dexamethasone—psoriasis	0.000745	0.000943	CcSEcCtD
Loxapine—Loss of consciousness—Betamethasone—psoriasis	0.000745	0.000943	CcSEcCtD
Loxapine—Dizziness—Mycophenolic acid—psoriasis	0.000745	0.000942	CcSEcCtD
Loxapine—Paraesthesia—Prednisolone—psoriasis	0.000744	0.000942	CcSEcCtD
Loxapine—Tachycardia—Triamcinolone—psoriasis	0.000744	0.000942	CcSEcCtD
Loxapine—Agranulocytosis—Methotrexate—psoriasis	0.000737	0.000932	CcSEcCtD
Loxapine—Convulsion—Betamethasone—psoriasis	0.000734	0.000929	CcSEcCtD
Loxapine—Convulsion—Dexamethasone—psoriasis	0.000734	0.000929	CcSEcCtD
Loxapine—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000732	0.000927	CcSEcCtD
Loxapine—Insomnia—Hydrocortisone—psoriasis	0.000732	0.000927	CcSEcCtD
Loxapine—Hypertension—Dexamethasone—psoriasis	0.000732	0.000926	CcSEcCtD
Loxapine—Hypertension—Betamethasone—psoriasis	0.000732	0.000926	CcSEcCtD
Loxapine—Paraesthesia—Hydrocortisone—psoriasis	0.000727	0.00092	CcSEcCtD
Loxapine—Vomiting—Mycophenolic acid—psoriasis	0.000716	0.000906	CcSEcCtD
Loxapine—Rash—Mycophenolic acid—psoriasis	0.00071	0.000898	CcSEcCtD
Loxapine—Dermatitis—Mycophenolic acid—psoriasis	0.000709	0.000898	CcSEcCtD
Loxapine—Hepatitis—Methotrexate—psoriasis	0.000709	0.000897	CcSEcCtD
Loxapine—Headache—Mycophenolic acid—psoriasis	0.000705	0.000893	CcSEcCtD
Loxapine—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000699	0.000885	CcSEcCtD
Loxapine—Fatigue—Hydrocortisone—psoriasis	0.000698	0.000883	CcSEcCtD
Loxapine—Vision blurred—Prednisone—psoriasis	0.000696	0.00088	CcSEcCtD
Loxapine—Oedema—Dexamethasone—psoriasis	0.000692	0.000875	CcSEcCtD
Loxapine—Oedema—Betamethasone—psoriasis	0.000692	0.000875	CcSEcCtD
Loxapine—Insomnia—Triamcinolone—psoriasis	0.000689	0.000873	CcSEcCtD
Loxapine—Paraesthesia—Triamcinolone—psoriasis	0.000684	0.000866	CcSEcCtD
Loxapine—Feeling abnormal—Prednisolone—psoriasis	0.000683	0.000864	CcSEcCtD
Loxapine—Shock—Dexamethasone—psoriasis	0.00068	0.000861	CcSEcCtD
Loxapine—Shock—Betamethasone—psoriasis	0.00068	0.000861	CcSEcCtD
Loxapine—Dyspnoea—Triamcinolone—psoriasis	0.00068	0.00086	CcSEcCtD
Loxapine—Nervous system disorder—Dexamethasone—psoriasis	0.000678	0.000858	CcSEcCtD
Loxapine—Nervous system disorder—Betamethasone—psoriasis	0.000678	0.000858	CcSEcCtD
Loxapine—Agitation—Prednisone—psoriasis	0.000678	0.000858	CcSEcCtD
Loxapine—Thrombocytopenia—Dexamethasone—psoriasis	0.000677	0.000857	CcSEcCtD
Loxapine—Thrombocytopenia—Betamethasone—psoriasis	0.000677	0.000857	CcSEcCtD
Loxapine—Tachycardia—Dexamethasone—psoriasis	0.000675	0.000854	CcSEcCtD
Loxapine—Tachycardia—Betamethasone—psoriasis	0.000675	0.000854	CcSEcCtD
Loxapine—Hypersensitivity—Cyclosporine—psoriasis	0.000671	0.000849	CcSEcCtD
Loxapine—Nausea—Mycophenolic acid—psoriasis	0.000669	0.000846	CcSEcCtD
Loxapine—Feeling abnormal—Hydrocortisone—psoriasis	0.000667	0.000844	CcSEcCtD
Loxapine—Syncope—Prednisone—psoriasis	0.000662	0.000838	CcSEcCtD
Loxapine—Fatigue—Triamcinolone—psoriasis	0.000657	0.000832	CcSEcCtD
Loxapine—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000655	0.000829	CcSEcCtD
Loxapine—Asthenia—Cyclosporine—psoriasis	0.000654	0.000827	CcSEcCtD
Loxapine—Loss of consciousness—Prednisone—psoriasis	0.000649	0.000821	CcSEcCtD
Loxapine—Hypotension—Dexamethasone—psoriasis	0.000646	0.000818	CcSEcCtD
Loxapine—Hypotension—Betamethasone—psoriasis	0.000646	0.000818	CcSEcCtD
Loxapine—Pruritus—Cyclosporine—psoriasis	0.000644	0.000816	CcSEcCtD
Loxapine—Angiopathy—Methotrexate—psoriasis	0.000643	0.000814	CcSEcCtD
Loxapine—Convulsion—Prednisone—psoriasis	0.000639	0.000809	CcSEcCtD
Loxapine—Mediastinal disorder—Methotrexate—psoriasis	0.000639	0.000808	CcSEcCtD
Loxapine—Asthenia—Mycophenolate mofetil—psoriasis	0.000638	0.000807	CcSEcCtD
Loxapine—Hypertension—Prednisone—psoriasis	0.000637	0.000806	CcSEcCtD
Loxapine—Pruritus—Mycophenolate mofetil—psoriasis	0.000629	0.000796	CcSEcCtD
Loxapine—Feeling abnormal—Triamcinolone—psoriasis	0.000628	0.000795	CcSEcCtD
Loxapine—Alopecia—Methotrexate—psoriasis	0.000626	0.000792	CcSEcCtD
Loxapine—Insomnia—Dexamethasone—psoriasis	0.000626	0.000792	CcSEcCtD
Loxapine—Insomnia—Betamethasone—psoriasis	0.000626	0.000792	CcSEcCtD
Loxapine—Paraesthesia—Dexamethasone—psoriasis	0.000621	0.000786	CcSEcCtD
Loxapine—Paraesthesia—Betamethasone—psoriasis	0.000621	0.000786	CcSEcCtD
Loxapine—Hypersensitivity—Prednisolone—psoriasis	0.000611	0.000773	CcSEcCtD
Loxapine—Dysgeusia—Methotrexate—psoriasis	0.000604	0.000764	CcSEcCtD
Loxapine—Dizziness—Cyclosporine—psoriasis	0.000602	0.000762	CcSEcCtD
Loxapine—Oedema—Prednisone—psoriasis	0.000602	0.000762	CcSEcCtD
Loxapine—Gastrointestinal disorder—Betamethasone—psoriasis	0.000597	0.000756	CcSEcCtD
Loxapine—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000597	0.000756	CcSEcCtD
Loxapine—Hypersensitivity—Hydrocortisone—psoriasis	0.000596	0.000755	CcSEcCtD
Loxapine—Fatigue—Betamethasone—psoriasis	0.000596	0.000755	CcSEcCtD
Loxapine—Fatigue—Dexamethasone—psoriasis	0.000596	0.000755	CcSEcCtD
Loxapine—Shock—Prednisone—psoriasis	0.000593	0.00075	CcSEcCtD
Loxapine—Nervous system disorder—Prednisone—psoriasis	0.000591	0.000748	CcSEcCtD
Loxapine—Tachycardia—Prednisone—psoriasis	0.000588	0.000744	CcSEcCtD
Loxapine—Dizziness—Mycophenolate mofetil—psoriasis	0.000588	0.000744	CcSEcCtD
Loxapine—Vision blurred—Methotrexate—psoriasis	0.000581	0.000736	CcSEcCtD
Loxapine—Asthenia—Hydrocortisone—psoriasis	0.000581	0.000735	CcSEcCtD
Loxapine—Vomiting—Cyclosporine—psoriasis	0.000579	0.000733	CcSEcCtD
Loxapine—Rash—Cyclosporine—psoriasis	0.000574	0.000727	CcSEcCtD
Loxapine—Dermatitis—Cyclosporine—psoriasis	0.000574	0.000726	CcSEcCtD
Loxapine—Pruritus—Hydrocortisone—psoriasis	0.000573	0.000725	CcSEcCtD
Loxapine—Headache—Cyclosporine—psoriasis	0.000571	0.000722	CcSEcCtD
Loxapine—Feeling abnormal—Betamethasone—psoriasis	0.00057	0.000721	CcSEcCtD
Loxapine—Feeling abnormal—Dexamethasone—psoriasis	0.00057	0.000721	CcSEcCtD
Loxapine—Vomiting—Mycophenolate mofetil—psoriasis	0.000565	0.000715	CcSEcCtD
Loxapine—Hypersensitivity—Triamcinolone—psoriasis	0.000562	0.000711	CcSEcCtD
Loxapine—Rash—Mycophenolate mofetil—psoriasis	0.00056	0.000709	CcSEcCtD
Loxapine—Dermatitis—Mycophenolate mofetil—psoriasis	0.00056	0.000708	CcSEcCtD
Loxapine—Headache—Mycophenolate mofetil—psoriasis	0.000557	0.000705	CcSEcCtD
Loxapine—Leukopenia—Methotrexate—psoriasis	0.000552	0.000699	CcSEcCtD
Loxapine—Dizziness—Prednisolone—psoriasis	0.000548	0.000694	CcSEcCtD
Loxapine—Asthenia—Triamcinolone—psoriasis	0.000547	0.000692	CcSEcCtD
Loxapine—Insomnia—Prednisone—psoriasis	0.000545	0.000689	CcSEcCtD
Loxapine—Nausea—Cyclosporine—psoriasis	0.000541	0.000685	CcSEcCtD
Loxapine—Paraesthesia—Prednisone—psoriasis	0.000541	0.000684	CcSEcCtD
Loxapine—Pruritus—Triamcinolone—psoriasis	0.000539	0.000683	CcSEcCtD
Loxapine—Cough—Methotrexate—psoriasis	0.000538	0.000681	CcSEcCtD
Loxapine—Dizziness—Hydrocortisone—psoriasis	0.000535	0.000677	CcSEcCtD
Loxapine—Convulsion—Methotrexate—psoriasis	0.000534	0.000676	CcSEcCtD
Loxapine—Nausea—Mycophenolate mofetil—psoriasis	0.000528	0.000668	CcSEcCtD
Loxapine—Chest pain—Methotrexate—psoriasis	0.000525	0.000665	CcSEcCtD
Loxapine—Rash—Prednisolone—psoriasis	0.000523	0.000661	CcSEcCtD
Loxapine—Dermatitis—Prednisolone—psoriasis	0.000522	0.000661	CcSEcCtD
Loxapine—Fatigue—Prednisone—psoriasis	0.000519	0.000657	CcSEcCtD
Loxapine—Headache—Prednisolone—psoriasis	0.000519	0.000657	CcSEcCtD
Loxapine—Constipation—Prednisone—psoriasis	0.000515	0.000652	CcSEcCtD
Loxapine—Vomiting—Hydrocortisone—psoriasis	0.000515	0.000651	CcSEcCtD
Loxapine—Rash—Hydrocortisone—psoriasis	0.00051	0.000646	CcSEcCtD
Loxapine—Dermatitis—Hydrocortisone—psoriasis	0.00051	0.000645	CcSEcCtD
Loxapine—Confusional state—Methotrexate—psoriasis	0.000508	0.000642	CcSEcCtD
Loxapine—Headache—Hydrocortisone—psoriasis	0.000507	0.000642	CcSEcCtD
Loxapine—Dizziness—Triamcinolone—psoriasis	0.000504	0.000638	CcSEcCtD
Loxapine—Feeling abnormal—Prednisone—psoriasis	0.000496	0.000628	CcSEcCtD
Loxapine—Asthenia—Dexamethasone—psoriasis	0.000496	0.000628	CcSEcCtD
Loxapine—Asthenia—Betamethasone—psoriasis	0.000496	0.000628	CcSEcCtD
Loxapine—Nervous system disorder—Methotrexate—psoriasis	0.000494	0.000625	CcSEcCtD
Loxapine—Thrombocytopenia—Methotrexate—psoriasis	0.000493	0.000624	CcSEcCtD
Loxapine—Nausea—Prednisolone—psoriasis	0.000492	0.000623	CcSEcCtD
Loxapine—Pruritus—Betamethasone—psoriasis	0.000489	0.000619	CcSEcCtD
Loxapine—Pruritus—Dexamethasone—psoriasis	0.000489	0.000619	CcSEcCtD
Loxapine—Vomiting—Triamcinolone—psoriasis	0.000485	0.000613	CcSEcCtD
Loxapine—Nausea—Hydrocortisone—psoriasis	0.000481	0.000609	CcSEcCtD
Loxapine—Rash—Triamcinolone—psoriasis	0.000481	0.000608	CcSEcCtD
Loxapine—Dermatitis—Triamcinolone—psoriasis	0.00048	0.000608	CcSEcCtD
Loxapine—Headache—Triamcinolone—psoriasis	0.000478	0.000604	CcSEcCtD
Loxapine—Hypotension—Methotrexate—psoriasis	0.00047	0.000595	CcSEcCtD
Loxapine—Dizziness—Betamethasone—psoriasis	0.000457	0.000579	CcSEcCtD
Loxapine—Dizziness—Dexamethasone—psoriasis	0.000457	0.000579	CcSEcCtD
Loxapine—Insomnia—Methotrexate—psoriasis	0.000455	0.000576	CcSEcCtD
Loxapine—Nausea—Triamcinolone—psoriasis	0.000453	0.000573	CcSEcCtD
Loxapine—Paraesthesia—Methotrexate—psoriasis	0.000452	0.000572	CcSEcCtD
Loxapine—Dyspnoea—Methotrexate—psoriasis	0.000449	0.000568	CcSEcCtD
Loxapine—Somnolence—Methotrexate—psoriasis	0.000448	0.000566	CcSEcCtD
Loxapine—Hypersensitivity—Prednisone—psoriasis	0.000444	0.000562	CcSEcCtD
Loxapine—Vomiting—Dexamethasone—psoriasis	0.00044	0.000557	CcSEcCtD
Loxapine—Vomiting—Betamethasone—psoriasis	0.00044	0.000557	CcSEcCtD
Loxapine—Rash—Betamethasone—psoriasis	0.000436	0.000552	CcSEcCtD
Loxapine—Rash—Dexamethasone—psoriasis	0.000436	0.000552	CcSEcCtD
Loxapine—Dermatitis—Dexamethasone—psoriasis	0.000436	0.000551	CcSEcCtD
Loxapine—Dermatitis—Betamethasone—psoriasis	0.000436	0.000551	CcSEcCtD
Loxapine—Gastrointestinal disorder—Methotrexate—psoriasis	0.000435	0.00055	CcSEcCtD
Loxapine—Fatigue—Methotrexate—psoriasis	0.000434	0.000549	CcSEcCtD
Loxapine—Headache—Betamethasone—psoriasis	0.000433	0.000548	CcSEcCtD
Loxapine—Headache—Dexamethasone—psoriasis	0.000433	0.000548	CcSEcCtD
Loxapine—Asthenia—Prednisone—psoriasis	0.000432	0.000547	CcSEcCtD
Loxapine—Pruritus—Prednisone—psoriasis	0.000426	0.000539	CcSEcCtD
Loxapine—Feeling abnormal—Methotrexate—psoriasis	0.000415	0.000525	CcSEcCtD
Loxapine—Nausea—Dexamethasone—psoriasis	0.000411	0.00052	CcSEcCtD
Loxapine—Nausea—Betamethasone—psoriasis	0.000411	0.00052	CcSEcCtD
Loxapine—Dizziness—Prednisone—psoriasis	0.000398	0.000504	CcSEcCtD
Loxapine—Vomiting—Prednisone—psoriasis	0.000383	0.000485	CcSEcCtD
Loxapine—Rash—Prednisone—psoriasis	0.00038	0.000481	CcSEcCtD
Loxapine—Dermatitis—Prednisone—psoriasis	0.000379	0.00048	CcSEcCtD
Loxapine—Headache—Prednisone—psoriasis	0.000377	0.000478	CcSEcCtD
Loxapine—Hypersensitivity—Methotrexate—psoriasis	0.000371	0.000469	CcSEcCtD
Loxapine—Asthenia—Methotrexate—psoriasis	0.000361	0.000457	CcSEcCtD
Loxapine—Nausea—Prednisone—psoriasis	0.000358	0.000453	CcSEcCtD
Loxapine—Pruritus—Methotrexate—psoriasis	0.000356	0.000451	CcSEcCtD
Loxapine—Dizziness—Methotrexate—psoriasis	0.000333	0.000421	CcSEcCtD
Loxapine—Vomiting—Methotrexate—psoriasis	0.00032	0.000405	CcSEcCtD
Loxapine—Rash—Methotrexate—psoriasis	0.000317	0.000402	CcSEcCtD
Loxapine—Dermatitis—Methotrexate—psoriasis	0.000317	0.000401	CcSEcCtD
Loxapine—Headache—Methotrexate—psoriasis	0.000315	0.000399	CcSEcCtD
Loxapine—Nausea—Methotrexate—psoriasis	0.000299	0.000378	CcSEcCtD
Loxapine—CHRM2—Signaling by GPCR—CXCL8—psoriasis	3.14e-05	0.00015	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—LEP—psoriasis	3.14e-05	0.000149	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—APOE—psoriasis	3.14e-05	0.000149	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—CXCL8—psoriasis	3.13e-05	0.000149	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—VEGFA—psoriasis	3.13e-05	0.000149	CbGpPWpGaD
Loxapine—ADRA2A—Hemostasis—TP53—psoriasis	3.11e-05	0.000148	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—VEGFA—psoriasis	3.11e-05	0.000148	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—STAT3—psoriasis	3.1e-05	0.000148	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—APOE—psoriasis	3.1e-05	0.000148	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—STAT3—psoriasis	3.08e-05	0.000147	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—NFKBIA—psoriasis	3.07e-05	0.000146	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TYK2—psoriasis	3.07e-05	0.000146	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—NFKBIA—psoriasis	3.05e-05	0.000146	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—TP53—psoriasis	3.05e-05	0.000145	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—NFKBIA—psoriasis	2.97e-05	0.000142	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—CXCL8—psoriasis	2.96e-05	0.000141	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—CXCL8—psoriasis	2.95e-05	0.000141	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—PPARG—psoriasis	2.94e-05	0.00014	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—CXCL8—psoriasis	2.93e-05	0.00014	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TYK2—psoriasis	2.92e-05	0.000139	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—NFKBIA—psoriasis	2.92e-05	0.000139	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—CXCL8—psoriasis	2.91e-05	0.000139	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—LEP—psoriasis	2.89e-05	0.000138	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—APOE—psoriasis	2.89e-05	0.000138	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TYK2—psoriasis	2.88e-05	0.000137	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—CXCL8—psoriasis	2.87e-05	0.000137	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—LEP—psoriasis	2.85e-05	0.000136	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—APOE—psoriasis	2.85e-05	0.000136	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—APOE—psoriasis	2.84e-05	0.000135	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—LEP—psoriasis	2.84e-05	0.000135	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—LEP—psoriasis	2.83e-05	0.000135	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—APOE—psoriasis	2.83e-05	0.000135	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—CXCL8—psoriasis	2.83e-05	0.000135	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—APOE—psoriasis	2.82e-05	0.000134	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—LEP—psoriasis	2.82e-05	0.000134	CbGpPWpGaD
Loxapine—HTR6—Signaling by GPCR—IL6—psoriasis	2.81e-05	0.000134	CbGpPWpGaD
Loxapine—HTR7—Signaling by GPCR—IL6—psoriasis	2.81e-05	0.000134	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—LEP—psoriasis	2.79e-05	0.000133	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—APOE—psoriasis	2.79e-05	0.000133	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—IL6—psoriasis	2.79e-05	0.000133	CbGpPWpGaD
Loxapine—HTR1D—Signaling by GPCR—IL6—psoriasis	2.79e-05	0.000133	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—CXCL8—psoriasis	2.79e-05	0.000133	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—LEP—psoriasis	2.79e-05	0.000133	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—APOE—psoriasis	2.79e-05	0.000133	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—JUN—psoriasis	2.75e-05	0.000131	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—JUN—psoriasis	2.75e-05	0.000131	CbGpPWpGaD
Loxapine—HTR1B—Signaling by GPCR—IL6—psoriasis	2.73e-05	0.00013	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—JUN—psoriasis	2.73e-05	0.00013	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PPARG—psoriasis	2.7e-05	0.000129	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—NFKBIA—psoriasis	2.69e-05	0.000128	CbGpPWpGaD
Loxapine—DRD4—Signaling by GPCR—IL6—psoriasis	2.69e-05	0.000128	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—CXCL8—psoriasis	2.67e-05	0.000127	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—JUN—psoriasis	2.67e-05	0.000127	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—TP53—psoriasis	2.66e-05	0.000127	CbGpPWpGaD
Loxapine—CHRM4—Signaling by GPCR—IL6—psoriasis	2.65e-05	0.000126	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—NFKBIA—psoriasis	2.65e-05	0.000126	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—NFKB1—psoriasis	2.65e-05	0.000126	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—NFKBIA—psoriasis	2.65e-05	0.000126	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—NFKB1—psoriasis	2.64e-05	0.000126	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—NFKBIA—psoriasis	2.64e-05	0.000126	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—NFKBIA—psoriasis	2.63e-05	0.000125	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—JUN—psoriasis	2.63e-05	0.000125	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TYK2—psoriasis	2.63e-05	0.000125	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—NFKB1—psoriasis	2.63e-05	0.000125	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TYK2—psoriasis	2.6e-05	0.000124	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—NFKBIA—psoriasis	2.6e-05	0.000124	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—NFKBIA—psoriasis	2.6e-05	0.000124	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—JUN—psoriasis	2.59e-05	0.000124	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—APOE—psoriasis	2.59e-05	0.000123	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—LEP—psoriasis	2.59e-05	0.000123	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—NFKB1—psoriasis	2.57e-05	0.000123	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—CXCL8—psoriasis	2.55e-05	0.000121	CbGpPWpGaD
Loxapine—CHRM5—Signaling by GPCR—IL6—psoriasis	2.54e-05	0.000121	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—NFKB1—psoriasis	2.53e-05	0.000121	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TYK2—psoriasis	2.51e-05	0.00012	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—CXCL8—psoriasis	2.51e-05	0.00012	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TYK2—psoriasis	2.5e-05	0.000119	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—NFKB1—psoriasis	2.5e-05	0.000119	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—JUN—psoriasis	2.48e-05	0.000118	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TYK2—psoriasis	2.43e-05	0.000116	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—IL6—psoriasis	2.43e-05	0.000116	CbGpPWpGaD
Loxapine—DRD1—Signaling by GPCR—IL6—psoriasis	2.42e-05	0.000115	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—NFKBIA—psoriasis	2.41e-05	0.000115	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—VEGFA—psoriasis	2.4e-05	0.000114	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—VEGFA—psoriasis	2.4e-05	0.000114	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TYK2—psoriasis	2.39e-05	0.000114	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—NFKB1—psoriasis	2.39e-05	0.000114	CbGpPWpGaD
Loxapine—DRD3—Signaling by GPCR—IL6—psoriasis	2.39e-05	0.000114	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—VEGFA—psoriasis	2.38e-05	0.000114	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—STAT3—psoriasis	2.38e-05	0.000113	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—STAT3—psoriasis	2.38e-05	0.000113	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—JUN—psoriasis	2.37e-05	0.000113	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—TP53—psoriasis	2.37e-05	0.000113	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—STAT3—psoriasis	2.36e-05	0.000112	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—TP53—psoriasis	2.35e-05	0.000112	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—JUN—psoriasis	2.33e-05	0.000111	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—VEGFA—psoriasis	2.33e-05	0.000111	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—STAT3—psoriasis	2.31e-05	0.00011	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—VEGFA—psoriasis	2.3e-05	0.000109	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—CXCL8—psoriasis	2.29e-05	0.000109	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—NFKB1—psoriasis	2.28e-05	0.000109	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—STAT3—psoriasis	2.27e-05	0.000108	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—CXCL8—psoriasis	2.27e-05	0.000108	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—VEGFA—psoriasis	2.27e-05	0.000108	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—NFKB1—psoriasis	2.25e-05	0.000107	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—STAT3—psoriasis	2.24e-05	0.000107	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TYK2—psoriasis	2.21e-05	0.000105	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CXCL8—psoriasis	2.19e-05	0.000104	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CXCL8—psoriasis	2.18e-05	0.000104	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—IL6—psoriasis	2.18e-05	0.000104	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TYK2—psoriasis	2.17e-05	0.000103	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—VEGFA—psoriasis	2.17e-05	0.000103	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TYK2—psoriasis	2.17e-05	0.000103	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—IL6—psoriasis	2.17e-05	0.000103	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TYK2—psoriasis	2.16e-05	0.000103	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—IL6—psoriasis	2.16e-05	0.000103	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TYK2—psoriasis	2.15e-05	0.000103	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—IL6—psoriasis	2.15e-05	0.000103	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—STAT3—psoriasis	2.15e-05	0.000102	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TYK2—psoriasis	2.13e-05	0.000102	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—JUN—psoriasis	2.13e-05	0.000101	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TYK2—psoriasis	2.13e-05	0.000101	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CXCL8—psoriasis	2.12e-05	0.000101	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—JUN—psoriasis	2.11e-05	0.0001	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CXCL8—psoriasis	2.08e-05	9.93e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—IL6—psoriasis	2.08e-05	9.92e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—IL6—psoriasis	2.07e-05	9.87e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—VEGFA—psoriasis	2.07e-05	9.85e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—NFKB1—psoriasis	2.05e-05	9.76e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—STAT3—psoriasis	2.05e-05	9.76e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—VEGFA—psoriasis	2.04e-05	9.72e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—JUN—psoriasis	2.03e-05	9.7e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—NFKB1—psoriasis	2.03e-05	9.67e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—JUN—psoriasis	2.02e-05	9.65e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—STAT3—psoriasis	2.02e-05	9.63e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—IL6—psoriasis	2.01e-05	9.6e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—IL6—psoriasis	1.98e-05	9.45e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TYK2—psoriasis	1.98e-05	9.42e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—JUN—psoriasis	1.97e-05	9.38e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—NFKB1—psoriasis	1.96e-05	9.33e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—NFKB1—psoriasis	1.95e-05	9.29e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—JUN—psoriasis	1.94e-05	9.24e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CXCL8—psoriasis	1.92e-05	9.16e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—NFKB1—psoriasis	1.9e-05	9.03e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CXCL8—psoriasis	1.89e-05	9.01e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CXCL8—psoriasis	1.89e-05	8.99e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CXCL8—psoriasis	1.88e-05	8.96e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CXCL8—psoriasis	1.87e-05	8.93e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—NFKB1—psoriasis	1.87e-05	8.89e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—VEGFA—psoriasis	1.86e-05	8.86e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CXCL8—psoriasis	1.86e-05	8.85e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CXCL8—psoriasis	1.85e-05	8.82e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—VEGFA—psoriasis	1.84e-05	8.78e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—STAT3—psoriasis	1.84e-05	8.77e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—IL6—psoriasis	1.83e-05	8.71e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—STAT3—psoriasis	1.82e-05	8.69e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—TP53—psoriasis	1.81e-05	8.65e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—TP53—psoriasis	1.81e-05	8.64e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—TP53—psoriasis	1.8e-05	8.58e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—IL6—psoriasis	1.8e-05	8.57e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—IL6—psoriasis	1.79e-05	8.55e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—IL6—psoriasis	1.79e-05	8.52e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—JUN—psoriasis	1.79e-05	8.51e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—IL6—psoriasis	1.78e-05	8.5e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—VEGFA—psoriasis	1.78e-05	8.47e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—VEGFA—psoriasis	1.77e-05	8.43e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—IL6—psoriasis	1.77e-05	8.41e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—TP53—psoriasis	1.76e-05	8.4e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—IL6—psoriasis	1.76e-05	8.39e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—STAT3—psoriasis	1.76e-05	8.39e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—JUN—psoriasis	1.76e-05	8.38e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—JUN—psoriasis	1.75e-05	8.36e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—STAT3—psoriasis	1.75e-05	8.35e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—JUN—psoriasis	1.75e-05	8.33e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—JUN—psoriasis	1.74e-05	8.31e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—TP53—psoriasis	1.73e-05	8.27e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—JUN—psoriasis	1.73e-05	8.23e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—JUN—psoriasis	1.72e-05	8.2e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CXCL8—psoriasis	1.72e-05	8.2e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—VEGFA—psoriasis	1.72e-05	8.2e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—NFKB1—psoriasis	1.72e-05	8.2e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TP53—psoriasis	1.71e-05	8.16e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—STAT3—psoriasis	1.7e-05	8.12e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—VEGFA—psoriasis	1.69e-05	8.07e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—NFKB1—psoriasis	1.69e-05	8.06e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—NFKB1—psoriasis	1.69e-05	8.05e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—NFKB1—psoriasis	1.68e-05	8.02e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—NFKB1—psoriasis	1.68e-05	8e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—STAT3—psoriasis	1.68e-05	7.99e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—NFKB1—psoriasis	1.66e-05	7.92e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—IL6—psoriasis	1.66e-05	7.92e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—IL6—psoriasis	1.66e-05	7.91e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—NFKB1—psoriasis	1.66e-05	7.9e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IL6—psoriasis	1.65e-05	7.86e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TP53—psoriasis	1.64e-05	7.81e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—IL6—psoriasis	1.64e-05	7.8e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL6—psoriasis	1.61e-05	7.69e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—JUN—psoriasis	1.6e-05	7.62e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL6—psoriasis	1.59e-05	7.57e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL6—psoriasis	1.57e-05	7.47e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TP53—psoriasis	1.56e-05	7.44e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—VEGFA—psoriasis	1.56e-05	7.44e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—STAT3—psoriasis	1.55e-05	7.37e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TP53—psoriasis	1.54e-05	7.34e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—NFKB1—psoriasis	1.54e-05	7.34e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—VEGFA—psoriasis	1.54e-05	7.32e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—VEGFA—psoriasis	1.53e-05	7.3e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—VEGFA—psoriasis	1.53e-05	7.28e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—VEGFA—psoriasis	1.52e-05	7.26e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—STAT3—psoriasis	1.52e-05	7.25e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—STAT3—psoriasis	1.52e-05	7.23e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—STAT3—psoriasis	1.51e-05	7.21e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—VEGFA—psoriasis	1.51e-05	7.19e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—STAT3—psoriasis	1.51e-05	7.19e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—VEGFA—psoriasis	1.5e-05	7.17e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL6—psoriasis	1.5e-05	7.15e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—STAT3—psoriasis	1.49e-05	7.12e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—STAT3—psoriasis	1.49e-05	7.1e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL6—psoriasis	1.43e-05	6.81e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL6—psoriasis	1.41e-05	6.72e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TP53—psoriasis	1.4e-05	6.69e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—VEGFA—psoriasis	1.4e-05	6.66e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TP53—psoriasis	1.39e-05	6.63e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—STAT3—psoriasis	1.38e-05	6.59e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TP53—psoriasis	1.34e-05	6.4e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TP53—psoriasis	1.34e-05	6.37e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TP53—psoriasis	1.3e-05	6.19e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL6—psoriasis	1.29e-05	6.13e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TP53—psoriasis	1.28e-05	6.1e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL6—psoriasis	1.27e-05	6.07e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL6—psoriasis	1.23e-05	5.86e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL6—psoriasis	1.22e-05	5.83e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL6—psoriasis	1.19e-05	5.67e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TP53—psoriasis	1.18e-05	5.62e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL6—psoriasis	1.17e-05	5.58e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TP53—psoriasis	1.16e-05	5.53e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TP53—psoriasis	1.16e-05	5.52e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TP53—psoriasis	1.15e-05	5.5e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TP53—psoriasis	1.15e-05	5.48e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TP53—psoriasis	1.14e-05	5.43e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TP53—psoriasis	1.14e-05	5.41e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL6—psoriasis	1.08e-05	5.14e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL6—psoriasis	1.06e-05	5.06e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL6—psoriasis	1.06e-05	5.05e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL6—psoriasis	1.06e-05	5.03e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TP53—psoriasis	1.06e-05	5.03e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL6—psoriasis	1.05e-05	5.02e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL6—psoriasis	1.04e-05	4.97e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL6—psoriasis	1.04e-05	4.96e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL6—psoriasis	9.66e-06	4.61e-05	CbGpPWpGaD
